Tumor-bearing mice were treated at 4-day intervals by tail-vein bolus injections of the monoclonal anti-CXCR4 antibody (mAb 12G5), known to block the binding of CXCL12 to CXCR4 and to inhibit CXCL12-evoked chemotaxis in vitro [29, 30]. This evidence concerns the gene CXCL12 and neoplasm.